Semaglutide and tirzepatide training for providers in Arizona

What this guide covers

Semaglutide and tirzepatide are prescription medications, and weight-loss programs built on them are one of the most requested services in cash-pay practices. Prescribing them well takes more than a protocol: patient selection, titration, labs, follow-up and a clear position on branded versus compounded product. This guide covers what providers need to know and where training fits.

It is general educational information. It does not replace the product labeling, current FDA guidance or your own clinical judgment.

Patient selection and safety

• Read the labeling. Both medications carry a boxed warning about the risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• Screen before you prescribe. Review medical history, current medications, pancreatitis and gallbladder history, pregnancy plans and whether the patient has type 2 diabetes. Baseline labs belong in the workup; a metabolic panel and HbA1c are common starting points.
• Plan the titration. Dosing starts low and escalates, and the schedule is set by the product used. Gastrointestinal effects are the most common reason patients stop, so expectations and a follow-up plan matter.
• Document consent. Include benefits, risks, expected course, what happens if the patient stops, and cost. See informed consent.

Branded versus compounded product

Where the medication comes from is now a major decision. FDA’s position on drug shortages and compounding has changed over time, and it determines when compounding semaglutide or tirzepatide is permitted. FDA has also warned about dosing errors and safety concerns with some compounded products. Check FDA’s current guidance and the product sources you use before you build a program around either option. See the FDA page on semaglutide medications.

Whatever you choose, tell patients plainly what they are receiving, keep records of the source, and have your medical director or counsel confirm the arrangement is compliant.

Who can prescribe and who carries out the order

See who can do what in Arizona, by license. If you run a weight-loss program without a prescriber of your own, you need a medical director who actually reviews charts and orders. See weight-loss medical director in Arizona and what a medical director does.

Building the program, not just the prescription

• Intake and labs that happen before the first dose.
• A follow-up schedule for dose changes, side effects and weight and metabolic markers.
• Clear pricing that separates visit fees, labs and the medication.
• A plan for stopping or maintaining, since patients ask about it from the first visit.
• Documentation and consent that match the product and source you use.

To model the economics with your own numbers, use the ROI calculator. Treat any result as an estimate.

Where training fits

Semaglutide and tirzepatide are covered in our Peptide Therapy Fundamentals course (1.5 days, $3,900, no prior peptide experience required). It includes a module on metabolic and weight-management peptides: the mechanism of semaglutide and tirzepatide, dosing and titration, patient assessment, baseline labs and monitoring, and how they relate to other metabolic peptides. GLP-1 agents are one part of a broader peptide curriculum, not a standalone course.

The Peptides Advanced course ($2,600) builds on it, and the two together are $5,800. Eligibility is MD, DO, NP, PA or RN with an active unrestricted license. See every course on the tuition and comparison page.

Sources and verification

Last reviewed: October 28, 2026, by Naomi Fayzulayev, FNP-BC, FNP-C. Verify requirements against the primary sources before relying on them:

• FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
• A.R.S. § 32-1601 — Nurse Practice Act definitions, including registered nurse practitioner
• Arizona State Board of Nursing (RN and NP licensing, advisory opinions)
• Arizona Regulatory Board of Physician Assistants
• AANP — State practice environment

Board websites sometimes block automated access, so open them in a normal browser. This guide is general educational information, not legal advice, and does not create a clinician-client or attorney-client relationship. Consult an Arizona healthcare attorney about your situation.

Frequently asked

• Can a nurse practitioner prescribe semaglutide or tirzepatide in Arizona?
  Arizona is listed by AANP as a full practice authority state, so NPs may evaluate and prescribe within their certification, training and competence. Confirm current rules with the Board of Nursing.
• Can an RN prescribe or start a GLP-1 program on their own?
  No. An RN does not prescribe. An RN may educate and administer under a prescriber's order and protocol.
• Is compounded semaglutide or tirzepatide allowed?
  It depends on FDA's current position on shortages and compounding, which has changed over time. Check FDA's current guidance and your sources before building a program around compounded product.
• Do I need special training to prescribe GLP-1 medications?
  No separate license is required beyond your own prescribing authority, but good practice includes training in patient selection, titration, labs, side effects and documentation.
• Does your Peptide Fundamentals course cover semaglutide and tirzepatide?
  Yes. It includes a module on metabolic and weight-management peptides covering semaglutide and tirzepatide, dosing and titration, assessment and baseline labs. It is part of a broader peptide curriculum, not a standalone GLP-1 course.
• Do I need a medical director to run a weight-loss program?
  If you do not have your own prescriber, yes. If you prescribe yourself, the practice may still want one for oversight. See the weight-loss medical director page.